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ABSTRACT 
Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease.  
Previous research has shown that antecedent conditions are less prevalent in ALS patients 
than the general population. Current research has suggested some conditions are 
protective against ALS. The purpose of this study is to examine the relationship between 
antecedent conditions and ALS, using age of diagnosis and disease duration.  
Methods: Patient data was obtained through the Emory ALS Clinic in Atlanta, Georgia. 
Patients’ histories were analyzed to see if they had any antecedent conditions (high blood 
pressure, high cholesterol, diabetes, obesity, asthma, arthritis, COPD, kidney disease, 
liver disease, non-ALS neurological disease, and thyroid disease) at their time of 
diagnosis. Patients with antecedent conditions compared with the control population 
(ALS patients without any antecedent diseases) are analyzed through chi square test to 
see the distributions on age of diagnosis and disease duration. Ordinal logistical 
regression modelling was completed to see the magnitude of effect antecedent conditions 
has on disease duration and age of diagnosis. 
Results: All antecedent conditions had an older age at ALS diagnosis than the control 
population except obesity, kidney disease, and liver disease (p<0.05). Disease duration 
was found to be significantly shorter compared to the control population when looking at 
high blood pressure, diabetes, obesity, arthritis, and kidney disease (p<0.05). When 
looking at the antecedent conditions as a whole, those with cardiovascular diseases, or 
between 1 and 3 diseases, had a very significant older age of diagnosis (p<0.0001), and a 
significant shorter disease duration (p<0.05). 
Conclusions: Antecedent conditions high blood pressure, high cholesterol, and COPD can 
be seen as protective against ALS due to their delayed age of diagnosis. A possible 
explanation is that these antecedent diseases could be biochemically neuroprotective 
against ALS in a currently unknown pathway. Antecedent disease association, with 
reduced disease duration, is likely due to the advanced age of the patient. 
KEYWORDS 
amyotrophic lateral sclerosis, antecedent condition, disease duration, diagnosis age, 
prognosis, high blood pressure, hypertension, high cholesterol, hyperlipidemia, 
dyslipidemia, obesity, diabetes, asthma, arthritis, COPD, chronic obstructive pulmonary 
disease, thyroid, kidney, liver
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Chapter I 
 
Introduction 
 
 Amyotrophic Lateral Sclerosis (ALS) is a debilitating neuromuscular disease that 
affects almost 4 in 100,000 people in the United States (Mehta et al., 2014). Those 
afflicted with the disease face losing control over major muscle groups such as arms, 
legs, and core muscles including their diaphragm. Only 5 to 10% of ALS is attributed to a 
familial gene; the majority is considered idiopathic (Andersen, 2000).  
Previous research on ALS shows a link connection those without common 
conditions having ALS (Korner et al., 2013; Mitchell et al., 2015). These common 
conditions, such as elevated blood pressure, high cholesterol, obesity, and diabetes were 
found to be less prevalent in the ALS population than a control population (Dorst et al., 
2011; Dupuis et al., 2008; Korner et al., 2013; Mitchell et al., 2015). 
Current literature suggests the association of certain factors, like age at diagnosis 
and gender of the patient, may lead to shorter disease duration in patients diagnosed with 
ALS. Emerging research now links several common conditions to either having no effect 
or lengthening disease duration. However, literature has not yet been able to fully explore 
the effects of these factors and common conditions on the patients’ age at diagnosis. This 
is an important factor as the younger an individual is at time of ALS diagnosis, the longer 
the disease duration will be (Wei et al., 2015; Wolf et al., 2014). 
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Chapter II 
 
LITERATURE REVIEW 
 
Overview 
 Amyotrophic lateral sclerosis (ALS) is a debilitating neurological disease that 
attacks the motor neurons. As of 2011, it affects nearly 4 per 100,000 people in the 
United States as of 2011 (Mehta et al., 2014). The cause of ALS is largely attributed to 
being idiopathic, with less than 10 percent being related to a familial gene. (Andersen, 
2000).  
 Prior to an ALS diagnosis, many patients consider themselves to be healthier than 
the general population (Turner, 2013). Some research has shown lifelong athletes having 
a higher risk of developing ALS than non-athletes (Chio et al., 2009). ALS does not 
directly relate to having an active lifestyle, but factors that are associated with an active 
lifestyle also lead to an increase in ALS susceptibility (Beghi, 2013; Huisman et al., 
2013; Valenti et al., 2005). 
 Current research is seeking to improve longevity after a patient receives a 
diagnosis of ALS. The only FDA-approved treatment, Riluzole, has been shown to 
improve longevity, but only when taken within the first 6 months of therapy (Cetin et al., 
2015). Common factors related t0 disease duration are age at onset, gender, and race 
(Jawaid, Murthy, et al., 2010; Korner et al., 2013; Watanabe et al., 2014; Wolf et al., 
2014). 
This study will attempt to analyze the relationship between many antecedent 
conditions and the disease duration and diagnosis age of ALS. More specifically, these 
conditions include cardiovascular (including hypertension, hyperlipidemia, obesity, and 
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diabetes), autoimmune (asthma, chronic obstructive pulmonary disease [COPD], thyroid 
disease, and arthritis), non-ALS neurological disease, kidney disease, and liver diseases. 
These diseases are of interest when they manifest in the patient prior to ALS diagnosis.  
Epidemiology of Amyotrophic Lateral Sclerosis 
Disease Duration 
 The average life expectancy of ALS patients is currently less than two years after 
diagnosis (Cetin et al., 2015). Researchers are looking at many variables in order to help 
give patients a more accurate prognosis. Currently known and accepted factors for 
survival include age at diagnosis, gender, body weight at diagnosis, and interval between 
onset and diagnosis (Gil et al., 2007; Wei et al., 2015; Wolf et al., 2014).  
 One line of current research is how concurrent illness in ALS patients affects 
disease duration (Korner et al., 2013; Moreau et al., 2012; Paganoni, Deng, Jaffa, 
Cudkowicz, & Wills, 2011). While some studies have found that common conditions; 
such as hyperlipidemia and diabetes did not affect the length of survival (Dedic et al., 
2012; Korner et al., 2013; Sutedja et al., 2011), other studies found that the common 
conditions did have a positive of negative effect (Moreau et al., 2012; Paganoni et al., 
2011).  Lung ability, (e.g. full vital capacity and maximal inspiratory capacity), was 
found to be an accurate predictor for disease duration (Schmidt et al., 2006). Uric acid 
and tauroursodeoxycholic (TUDCA) acid, a hydrophilic bile, have also been linked with 
a prolonged survival in ALS patients (Elia et al., 2015; Paganoni et al., 2012). There are 
currently no studies that have successfully demonstrated a link between ALS disease 
duration and other non-ALS neurological diseases.  
 
Age of Diagnosis Models 
 An accepted variable to predict disease duration in ALS patients is age at 
diagnosis; however, the age at which an individual will be diagnosed cannot be predicted. 
Within the general population, ALS increases in prevalence with increasing age, reaching 
a peak at the 60-69 age range (Mehta et al., 2014). Research supports the stance that 
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ethnicity has a role in the age of diagnosis, as those with Asian race are found to be 
diagnosed at an earlier age than Caucasians (Wei et al., 2015). 
 Comparing age of diagnosis with antecedent conditions, diabetes mellitus type 2 
is found to be correlated with a later onset of 4 years compared to those without diabetes, 
adjusting for gender, ethnicity, and site of onset (Jawaid, Salamone, et al., 2010). Body 
mass index (BMI) at time of diagnosis was not found to have an association with age of 
onset (Jawaid, Murthy, et al., 2010).      
 
Antecedent Conditions of Interest 
Cardiovascular Conditions 
 For this study, cardiovascular conditions of interest include hyperlipidemia (high 
cholesterol), hypertension (high blood pressure), obesity (BMI greater than or equal to 
30.0), and diabetes mellitus (both type 1 and type 2). Many studies have examined these 
cardiovascular diseases within the same population but the effects of combinations of 
these diseases are relatively unstudied (Korner et al., 2013; Mitchell et al., 2015). 
 Hyperlipidemia – Hyperlipidemia is a commonly studied antecedent condition 
among ALS patients. Some studies have found that the presence of 
hyperlipidemia can extend the length of survival after diagnosis (Dedic et al., 
2012; Dorst et al., 2011; Dupuis et al., 2008; Sutedja et al., 2011). Other studies 
have found hyperlipidemia to not be related to disease duration (Korner et al., 
2013; Paganoni et al., 2011; J. W. Yang et al., 2013).  
 Hypertension – In research, hypertension has shown a mixed association with the 
disease duration in ALS patients. Relating to effect on disease duration, 
hypertension has been shown to be beneficial (Sutedja et al., 2011), neutral 
(Korner et al., 2013), and detrimental (Moreau et al., 2012). 
 Diabetes – In ALS patients, diabetes is less prevalent than the general population 
(Mariosa, Kamel, Bellocco, Ye, & Fang, 2015; Mitchell et al., 2015). Research 
has also shown patients with diabetes to have a 4 year later onset of ALS 
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compared to ALS patients without diabetes (Jawaid, Salamone, et al., 2010). 
However, it also has been shown to not have any effect on survival length (Korner 
et al., 2013). 
 Obesity – Obesity is primarily studied in regards to the BMI calculation itself, not 
the categories affected by BMI. Studies have shown that those with a lower BMI, 
between 18.5 and 24.9 or the ‘healthy’ range, are found to be at a higher risk of 
ALS than individuals with a higher BMI (Mitchell et al., 2015; O'Reilly et al., 
2013). Survival models have shown that a slower rate of change in BMI after 
diagnosis is related to longer disease duration (Jawaid, Murthy, et al., 2010; 
Paganoni et al., 2011; Sutedja et al., 2011). 
 
Autoimmune Conditions 
 Autoimmune conditions of interest include asthma, COPD, arthritis, and thyroid 
disease. Some studies have found that these conditions are found at a higher prevalence 
in the ALS population compared to the general population (Turner, Goldacre, 
Ramagopalan, Talbot, & Goldacre, 2013). However, other studies have found these 
conditions are at a lower prevalence (Mitchell et al., 2015). These conditions can be 
related to pulmonary function, which is found to be a direct predictor of disease duration 
in ALS patients (Schmidt et al., 2006). Autoimmune therapies have been shown to help 
slow the progression of ALS, as there are similar pathways that lead to the development 
of autoimmune diseases and ALS (Alexianu, 1995; Schulte-Herbruggen, Braun, 
Rochlitzer, Jockers-Scherubl, & Hellweg, 2007; E. J. Yang et al., 2010) 
 
Other Conditions 
 Kidney and liver diseases have not been extensively studied in ALS populations, 
but have been found to be less prevalent when compared to the general population 
(Mitchell et al., 2015). Uric Acid, which can be an indicator of kidney function, was 
found to be associated with longer disease duration in male ALS patients (Johnson et al., 
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2013; Paganoni et al., 2012). TUDCA (a hydrophilic bile in the liver) has been shown in 
a pilot study to improve the ALSFRS-R (ALS functional ratings scale) scores (Elia et al., 
2015).  
Neurological diseases, such as dementia and Parkinson’s, have conflicting 
associations with ALS. These range from being more common in ALS patients compared 
to general population, or not being related to the ALS diagnosis, to being less prevalent 
(Korner et al., 2013; Mitchell et al., 2015; van Doormaal et al., 2013). Multiple Sclerosis 
is one neurologic disease with research indicating such a correlation (Etemadifar, Abtahi, 
Akbari, & Maghzi, 2012) and there being no correlation (van Doormaal et al., 2013) 
within ALS patients. 
 
Previous Research 
The ALS patients included in this study have previously been examined for the 
prevalence of common conditions relative to the general population (Mitchell et al., 
2015).  The population of 1288 patients were examined for multiple pre-existing 
conditions, then matched with a control population based age, gender, and geographic 
region. The pre-existing conditions studied include hypertension, hyperlipidemia, 
diabetes, obesity, asthma, arthritis, COPD, thyroid disease, liver disease, non-ALS 
neurological disease, and kidney disease.  
Results showed that the ALS patients had lower prevalence of all diseases of 
interest when age, gender, and spatially matched to the general population. The ALS odds 
of arthritis (OR = 0.14), non-ALS neurological disease (OR = 0.14), liver disease (OR= 
0.19), chronic obstructive pulmonary disorder or COPD (OR = 0.23), kidney disease (OR 
= 0.32), adult asthma (OR = 0.39), diabetes (OR = 0.47), hypertension (OR = 0.56), 
obesity (OR = 0.6), hyperlipidemia or hypercholesterolemia (OR = 0.62), and thyroid 
disease (OR = 0.78) were lower than the odds of those in the general population. See 
Table A for the 95% confidence intervals.     
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There are two pathways to explain the lower prevalence. One method is “Other 
condition as ALS protection”, where the presence of antecedent conditions is protective 
against ALS. This could through a currently unknown biochemically neuroprotective 
pathway. Another explanation is “ALS as other condition protection” where the ALS 
disease interferes with the underlying causes of the antecedent conditions.  
Table A. Associations of ALS with odds of antecedent conditions.  Parameters are odds-
ratio (OR) and 95% confidence interval (CI).   The prevalence of each condition is less in 
ALS compared to the age and gender ratio-matched control condition 
Condition Odds Ratio, (95% 
Confidence Interval) 
Arthritis  0.14, (0.11, 0.18) 
Neurological 
Disease 
 0.14, (0.07, 0.27) 
Liver Disease  0.19,  (0.10, 0.35) 
COPD  0.23, (0.16, 0.32) 
Kidney Disease  0.32, (0.18, 0.57) 
Asthma  0.39, (0.30, 0.51) 
Diabetes  0.47, (0.38, 0.58) 
Hypertension  0.56, (0.49, 0.64) 
Obesity  0.60, (0.49, 0.74) 
Hyperlipidemia  0.62, (0.54, 0.71) 
Thyroid Disease  0.78, (0.60, 1.02) 
 
Purpose of Research 
 There are several different factors that have been examined individually for their 
effect on the prognosis in those with ALS, with some examining a larger array of 
conditions. This study will analyze the relationships between individual conditions and 
ALS patients. The conditions will also be analyzed together on ALS disease duration and 
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age of diagnosis to see if there is any interaction within the antecedent conditions.  
Logistic regression will be done to shed light on possible factors for age of diagnosis, 
along with clarifying the impact the antecedent conditions have. This will help clarify 
avenues for future research to understand underlying causes of ALS along with possible 
areas to focus when creating new treatments.  
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Chapter III 
 
Abstract 
 
Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease.  
Previous research has shown that antecedent conditions are less prevalent in ALS patients 
than the general population. Current research has suggested some conditions are 
protective against ALS. The purpose of this study is to examine the relationship between 
antecedent conditions and ALS, using age of diagnosis and disease duration.  
Methods: Patient data was obtained through the Emory ALS Clinic in Atlanta, Georgia. 
Patients’ histories were analyzed to see if they had any antecedent conditions (high blood 
pressure, high cholesterol, diabetes, obesity, asthma, arthritis, COPD, kidney disease, 
liver disease, non-ALS neurological disease, and thyroid disease) at their time of 
diagnosis. Patients with antecedent conditions compared with the control population 
(ALS patients without any antecedent diseases) are analyzed through chi square test to 
see the distributions on age of diagnosis and disease duration. Ordinal logistical 
regression modelling was completed to see the magnitude of effect antecedent conditions 
has on disease duration and age of diagnosis. 
Results: All antecedent conditions had an older age at ALS diagnosis than the control 
population except obesity, kidney disease, and liver disease (p<0.05). Disease duration 
was found to be significantly shorter compared to the control population when looking at 
high blood pressure, diabetes, obesity, arthritis, and kidney disease (p<0.05). When 
looking at the antecedent conditions as a whole, those with cardiovascular diseases, or 
between 1 and 3 diseases, had a very significant older age of diagnosis (p<0.0001), and a 
significant shorter disease duration (p<0.05).
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Conclusions: Antecedent conditions high blood pressure, high cholesterol, and COPD can 
be seen as protective against ALS due to their delayed age of diagnosis. A possible 
explanation is that these antecedent diseases could be biochemically neuroprotective 
against ALS in a currently unknown pathway. Antecedent disease association, with 
reduced disease duration, is likely due to the advanced age of the patient. 
 
Introduction 
 Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease 
with a relatively unknown etiology. Many times, those diagnosed with ALS have 
previously led healthy and active lifestyles (Huisman et al., 2013; Turner, 2013). 
Researchers have looked at multiple antecedent conditions to see if there is any link 
between these conditions and ALS, yet there have been no conclusive results (Dedic et 
al., 2012; Etemadifar et al., 2012; Jawaid, Salamone, et al., 2010; Korner et al., 2013; 
Paganoni et al., 2012). Only 5 to 10 percent of the ALS population can be attributed to 
genetic factors (Andersen, 2000) while the rest are idiopathic. 
 Existing research has found several factors that impact disease duration and age of 
onset of ALS in patients. Onset age has been found to occur earlier in those of Asian 
race, or male gender (Watanabe et al., 2014; Wei et al., 2015). Shorter disease duration is 
related to patients that have a more advanced age at onset of ALS symptoms (Gil et al., 
2007; Jawaid, Murthy, et al., 2010; Watanabe et al., 2014). 
 When looking at antecedent conditions, it has been shown that the ALS patients 
have lower rates than that of the general public (Korner et al., 2013; Mitchell et al., 
2015). These lower rates have led to speculation that the conditions could act as 
protection against ALS, possibly due to the hyper-metabolic state found in ALS patients 
(Jawaid, Salamone, et al., 2010).  
The effect of these conditions have been shown to have a positive (Dorst et al., 
2011; Moreau et al., 2012; Paganoni et al., 2012), neutral (Dedic et al., 2012; Korner et 
al., 2013), or negative (Jawaid, Murthy, et al., 2010) effect on duration of ALS in 
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patients. The effect on age at diagnosis is more consistent when studied, and shows a 
delayed age of diagnosis (Jawaid, Salamone, et al., 2010; Korner et al., 2013).  
This study will focus on how multiple types of antecedent conditions (high blood 
pressure, high cholesterol, diabetes, obesity, asthma, arthritis, COPD [Chronic 
Obstructive Pulmonary Disease], thyroid disease, kidney disease, liver disease, and non-
ALS neurological disease) effect ALS through diagnosis age and disease duration. 
Methods 
A case control study of antecedent conditions on diagnosis age and disease 
duration of an ALS population was performed. The ALS population consisted of 1439 
patients from the Emory ALS Clinic, in Atlanta Georgia confirmed to have ALS at their 
first clinic visit. The Internal Review Boards of Emory University, Georgia Institute of 
Technology, and Georgia State University approved all protocols of this study.  
 
Antecedent Conditions 
 The prevalence of high blood pressure, high cholesterol, diabetes, obesity, 
arthritis, asthma, COPD, thyroid disease, neurological disease (excluding ALS), kidney 
disease and liver disease were assessed at the first visit by medical personnel and a self-
completed patient entry survey. Additional information for gathering the data can be seen 
in a previously published paper (Mitchell et al., 2015).  
 
Study Populations 
 Two study populations were identified from the ALS clinic population. Control 
population was determined by the confirmed ALS patients having no antecedent 
conditions of interest at their first visit. The antecedent conditions population was 
determined by the ALS patients having at least one of the following: high blood pressure, 
high cholesterol, diabetes, obesity, arthritis, asthma, COPD, thyroid disease, neurological 
disease, kidney disease, or liver disease, at their first visit. 
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 These study populations were then analyzed to see if they met the qualifications 
of the two groups of interest. All patients were included in Group 1(n=1349). Group 1 
included patients with a confirmed diagnosis age. Those with a date of death in their 
medical records were also placed in Group 2 (n=787). Group 2 was used to analyze 
disease duration with ALS patients. 
 
Statistical Analysis 
 All statistical tests were completed using SAS 9.3. Chi square analysis was done 
to compare the distributions of the control population and antecedent disease population 
for both outcomes of interest. For age of diagnosis, the chi square compared the 
distribution above and below the mean age of diagnosis of the entire population. For the 
length of survival, the chi square compared the distribution above and below the mean 
length of survival of the subset of the total population. The distributions were compared 
between the control group and the antecedent disease group for both the age of diagnosis 
and survival length. 
 Ordinal logistic regression was completed for both age of diagnosis and length of 
survival to assess for confounders and compare the antecedent diseases with known risk 
factors. This was done to examine what extent each of the antecedent diseases and other 
factors related to the age of diagnosis and survival length.  
 For both models, male gender and Caucasian race were set as the reference 
group. Race was assessed as Caucasian, African American, and Other. The ordinal 
logistic regression for age of diagnosis included all antecedent diseases, race, and gender. 
The ordinal logistic regression for length of survival included all antecedent diseases, 
race, gender, and age of diagnosis.  
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Results 
Demographics 
Group 1, consisting of those who had a confirmed ALS diagnosis,  is 60% male 
and 40% female, with 57% of the population having at least one antecedent condition. 
Group 2, those who had a confirmed ALS diagnosis and date of death, is 57.7% male and 
42.3% female, along with 54% having at least one antecedent condition. Gender falls on 
a more equal distribution in group 2 than group 1(p<0.05). All of the antecedent 
conditions except high cholesterol, diabetes, and obesity occur within the same 
distribution between both population groups. (See Table 1 for additional demographic 
information) 
Group 1, those with a confirmed ALS diagnosis, has a diagnosis age mean of 60.1 
years with a standard deviation of 12.5 years. The mean diagnosis age among the control 
population was 56.6 years; males at 54.5 and females at 59.1 years of age. Those with 
antecedent disease had an average of 63.1 years; males at 62.4 years and females at 64.1 
years of age.  A substantially greater proportion of individuals with antecedent conditions 
are older when compared to those without antecedent conditions of interest (p<0.0001).  
Group 2 has average disease duration of 2.1 years with a standard deviation of 2.1 
years. Those without antecedent conditions of interest have an average of 2.4 years; with 
males at 2.5 and females at 2.4 years of survival. Those with antecedent conditions have 
disease duration of 1.9 years; with males at 2.0 and females at 1.7 years of survival. The 
antecedent condition group had a substantially shorter disease duration when compared 
with those without antecedent conditions (p<0.0001).  
 
Chi Square Analysis 
 Chi Square test was used to compare age of diagnosis and disease duration 
between antecedent conditions and those without any antecedent conditions. Antecedent 
condition populations include: Sole condition (only having one antecedent condition of 
interest), Multiple condition (having multiple antecedent conditions including the 
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condition of interest), Cardiovascular (having any number of the following: High blood 
pressure, High cholesterol, Diabetes, or Obesity), Autoimmune (having any of the 
following: Asthma, Arthritis, COPD, Thyroid disease), and finally Amount (the number 
of any antecedent conditions present). For example, a patient with the conditions of 
diabetes and asthma would be located in the Multiple condition group for asthma and for 
diabetes, the cardiovascular group, the autoimmune group, and the Amount group of 2.  
Sole and Multiple condition populations are found in Table 2. Cardiovascular, 
Autoimmune, and Amount populations are found in Table 3.  Mean age of diagnosis and 
disease duration of the antecedent condition populations are reported along with the 
number of patients analyzed for that comparison within the tables. 
Age of Diagnosis 
 High blood pressure and high cholesterol are found to have a substantially 
significant older distribution than the control ALS population as Sole antecedent 
condition, or Multiple antecedent condition (p<0.0001). A significant later age of 
diagnosis distribution is also found for diabetes, asthma, arthritis, COPD, thyroid 
diseases, and non-ALS neurological diseases, in Multiple antecedent condition groups 
(p<0.05).  
 In the cardiovascular group, substantial significance for a later age of diagnosis 
distribution is found for all categories except the four cardiovascular conditions group 
(p<0.001). Autoimmune conditions only show substantial significance when other 
antecedent diseases are involved for having a later age of diagnosis distribution than the 
control (p<0.0001). 
Up to three antecedent condition groups have a substantially significantly older 
distribution (p<0.0001). Those with four antecedent conditions have a significant older 
distribution at diagnosis (p<0.05). There is no significance found for those with five or 
six antecedent conditions.   
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Disease Duration 
 High blood pressure, high cholesterol, diabetes, obesity, arthritis and kidney 
disease all have a different distribution than the control for Multiple antecedent 
conditions (p<0.05). The significance found shows that those antecedent condition 
populations have a shorter disease duration that the control population. 
Cardiovascular conditions show significance for disease duration for one, two, 
and three conditions or having any cardiovascular condition at all (p<0.005).  Those 
categories are correlated to a shorter disease duration when compared to the control 
population.  
Amount antecedent conditions of one, two, and three results in a substantially 
shorter disease duration than the control (p<0.0005). Significance is not found in those 
with four, five, or six antecedent conditions due to a limiting sample size.  
 
Ordinal Logistical Regression 
Ordinal logistical regression modelling is used for age of diagnosis and disease 
duration. High blood pressure, high cholesterol, COPD, ‘Other’ race, and gender were 
found to be significant variables with an association to a delayed the age of diagnosis past 
the mean (60.1 years). ‘African American’ race and obesity are found to have a 
significant association to an earlier age of diagnosis. When looking at disease duration, 
age of diagnosis and ‘Other’ race are significant variables associated with shortening 
disease duration under the mean (2.1 years). ‘African American’ race has a significant 
association with lengthening disease duration beyond the mean. See Table 4 for the odds 
ratios for all variables tested.  
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Other Results 
The population was gender stratified to look for additional patterns. Significance 
results mirror that of the overall population for both genders. Antecedent conditions were 
also analyzed with permutations of two antecedent conditions. Significance is only found 
in the more prevalent condition permutations, such as high blood pressure and high 
cholesterol, where a large sample size is present. Any significance is reflected in the 
grouping of diseases.  
 
Discussion 
 Results of the chi square analysis indicates an overall pattern that those with 
antecedent conditions have a later age of diagnosis, and shorter disease duration, than 
those without antecedent conditions within the ALS population. When controlled for 
confounders, only high blood pressure, high cholesterol, obesity, and COPD are found to 
be significant factors in diagnosis age.  
 
Antecedent Conditions on Age of Diagnosis 
 When looking at individual antecedent conditions, every condition of interest is 
found to have a later age of diagnosis excluding obesity (see What about Obesity?).  High 
blood pressure, high cholesterol, and COPD are found to be significant factors in 
delaying the age of diagnosis. These conditions have also been found to be less prevalent 
in the ALS population (Korner et al., 2013; Mitchell et al., 2015; Sutedja et al., 2011).  
With the prevalence lower in the ALS population, there may be a mechanism in 
which these antecedent conditions are protective against ALS in an unknown pathway. 
Diabetes and high cholesterol have been previously suggested to be biochemically 
neuroprotective against ALS (Dupuis et al., 2008; Jawaid, Salamone, et al., 2010). 
ALS could possibly develop due to hypervigilance of the body’s systems, which 
can be seen with hyper-metabolism in patients, which could also explain the delayed 
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onset (Desport, Torny, Lacoste, Preux, & Couratier, 2005; Jawaid, Salamone, et al., 
2010; J. W. Yang et al., 2013). If the body has a lower level of hypervigilance, it would 
allow these antecedent conditions to form (Mitchell et al., 2015). The less severe 
hypervigilance would, as a separate function, cause ALS to develop at a later age. Those 
with a higher level of hypervigilance would not develop antecedent conditions, but would 
develop ALS at an earlier age.  
 
Antecedent Conditions on Disease Duration 
 No antecedent conditions are found to be significant factors in predicting the 
disease duration in patients. Some researchers have found that cardiovascular conditions 
are beneficial to ALS patients as ALS progresses (Dorst et al., 2011; Dupuis et al., 2008), 
but further research supports that the conditions do not have a significant impact on ALS 
disease duration (Dedic et al., 2012; Korner et al., 2013; Paganoni et al., 2011). 
The shorter disease duration found in the antecedent condition groups can be 
attributed to the fact that those groups have a later age of diagnosis. Advanced age is 
known to be a predictor of shorter disease duration (Gil et al., 2007; Watanabe et al., 
2014). Antecedent conditions are found more in older patients whether due to the 
condition protecting against ALS, or the prevalence of the conditions increasing with age.  
 
What about Obesity? 
 Obesity is the only antecedent condition found to be a significant predictor of a 
younger age of diagnosis. Many studies show that obesity can be beneficial to ALS 
patients in terms of survival (Jawaid, Murthy, et al., 2010; Shimizu et al., 2012). Other 
research has found obesity to be less prevalent in ALS patients than the general 
population (Mitchell et al., 2015; O'Reilly et al., 2013; Paganoni et al., 2011).  While 
these results (shorter disease duration) appear to be conflicting, further understanding of 
how the variables were defined is needed. 
18 
 
 
 When obesity is found to be beneficial to survival, the variable measured is the 
rate of change in BMI (Jawaid, Murthy, et al., 2010; Shimizu et al., 2012). Other studies 
have focused on unhealthy weight, taking any BMI above 24.9 to be considered of 
interest, with the effects varying as BMI changes (O'Reilly et al., 2013; Paganoni et al., 
2011).  
Our measure of obesity is a BMI greater than or equal to 30.0 at the time of 
diagnosis and change in BMI is not reflected in our study. Obesity likely has multifaceted 
implications on the disease duration and diagnosis of ALS that cannot be interpreted with 
this broad and static definition used.  
 
Limitations 
 One limitation is lack of complete demographic information. Many 
patients did not have a race in their records, or declined to give their race. This resulted 
grouping a large portion of the patients into the ‘Other’ race category. Sample size is also 
a limitation throughout the study. Despite the large overall population used, less than 25 
individuals are found to have thyroid disease, kidney disease, liver disease, or non-ALS 
neurological disease. A larger population of ALS patients with these antecedent 
conditions would allow for more accurate results.   
 
Conclusion 
 Antecedent conditions, found less prevalent in ALS patients than the general 
population, are also found to have an effect of the age of diagnosis. High blood pressure, 
high cholesterol, and COPD are found to be significant factors associated in delaying the 
age of diagnosis. Obesity was found to be a significant factor associated in an earlier age 
of diagnosis, most likely due to an improper classification and its complex effects in ALS 
patients. The delay of age of diagnosis among those with antecedent conditions could be 
due to the hyper-metabolic or hyper-vigilant state present in ALS patients.  
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Appendix A 
 
  
Table 1. Demographics of Emory Clinic ALS population by Diagnosis Age and Disease Duration 
Population 
Characteristics 
Diagnosis Age Population Disease Duration Population 
Overall Control Disease Overall Control Disease 
N 1439 619 820 787 364 423 
Age
# ⱡ
  
mean (SD) 60.1 (12.5) 56.6(13.3) 63.1 (8.0) 61.2(12.4) 57.4 (13.2) 64.5 (10.6) 
Survival Length 
(years) 
 
mean (SD)
ⱡ
 - - - 2.1 (2.1) 2.4 (2.3) 1.9 (1.8) 
Gender*  %(N)  
Male
ⱡ
 60.0 (864) 62.7 (388) 58.0 (476) 57.7 (454) 61.5 (224) 54.4 (230) 
Female
ⱡ
 40.0 (575) 37.3 (231) 42.0 (344) 42.3 (333) 38.5 (140) 45.6 (193) 
Race %(N)  
Caucasian 57.4 (826) 56.4 (349) 58.4 (479) 59.1 (465) 57.1 (208) 60.8 (257) 
African American 12.3 (177) 12.4 (77) 12.2 (100) 10.7 (84) 11.0 (40) 10.4 (44) 
Other 30.2 (434) 31.1 (193) 29.4 (241) 30.2 (238) 32.7 (119) 28.1 (119) 
Antecedent 
Conditions %(N) 
 
High Blood Pressure 40.0 (532) - 64.9 (532) 36.0 (283) - 66.9 (283) 
High Cholesterol* 26.3 (378) - 46.1 (378) 24.0 (189) - 44.7 (189) 
Diabetes* 7.7 (111) - 13.5 (111) 6.4 (50) - 11.8 (50) 
Obesity* 9.0 (129) - 15.7 (129) 7.1 (56) - 13.2 (56) 
Arthritis 5.1 (74) - 9.0 (74) 5.0 (39) - 9.2 (39) 
Asthma 4.9 (71) - 8.7 (71) 4.8 (38) - 9.0 (38) 
COPD 3.1 (45) - 5.5 (45) 2.8 (22) - 5.2(22) 
Thyroid 1.5 (22) - 2.7 (22) 1.8 (14) - 3.3 (14) 
Neurological disease 0.8 (11) - 1.3 (11) 1.0 (8) - 1.9 (8) 
Kidney Disease 0.8 (12) - 1.5 (12) 1.3 (10) - 2.4 (10) 
Liver Disease 0.8 (12) - 1.5 (12) 0.9 (7) - 1.7 (7) 
#
Age at first visit to clinic 
*Age of Diagnosis population significantly different than Disease Duration Population (p<0.05) 
ⱡ Control population significantly different than antecedent condition population (p<0.05) 
24 
 
 
Table 2. Antecedent Condition Effect of Age of Diagnosis and Disease Duration of ALS Population, Chi 
Square Analysis 
 
Age of Diagnosis Disease Duration 
Population Mean (s.d) N† P-value Mean (s.d) N† P-value 
Control* 56.2 (13.3) 1439 <.0001 2.4 (2.3) 787 <.0001 
Antecedent Condition  
Blood pressure       
Sole 63.4 (10.5) 819 <.0001 1.9 (2.0) 481 0.0079 
Multiple 64.3 (10.5) 1151 <.0001 1.8 (1.7) 647 <.0001 
Cholesterol  
Sole 63.3 (10.4) 718 <.0001 1.9 (1.5) 404 0.0612 
Multiple 65.3 (10.2) 997 <.0001 1.7 (1.5) 553 <.0001 
Diabetes  
Sole** 50.6 (12.8) 631 0.1410 3.2 (3.3) 371 0.7035 
Multiple 63.6 (10.1) 730 <.0001 1.8 (1.8) 414 0.002 
Obesity  
Sole 52.9 (9.6) 654 0.0185 1.6 (0.9) 379 0.4646 
Multiple 57.3 (11.1) 750 0.3847 1.7 (1.2) 421 0.0347 
Asthma  
Sole 56.0 (11.9) 641 0.4821 3.0 (2.0) 377 0.1819 
Multiple 61.1 (12.1) 690 0.0367 2.3 (1.7) 402 0.6881 
Arthritis  
Sole
 ‡ 60.3 (9.0) 638 0.2404 2.3 (2.3) 373 0.7382 
Multiple 65.6 (8.4) 693 <.0001 1.8 (1.9) 403 0.0379 
COPD  
Sole
 ‡ 60.4 (16.1) 634 0.2707 2.7 (3.7) 370 1 
Multiple 64.3 (11.8) 664 <.0001 1.9 (2.5) 386 0.5496 
Thyroid  
Multiple 67.4 (7.4) 641 0.0004 2.5 (2.1) 378 0.2899 
Neurological  
Multiple** 68.7 (7.1) 630 0.0007 1.8 (2.1) 372 0.1457 
Kidney  
Multiple** 69.4 (13.5) 631 0.0732 0.9 (0.6) 374 0.0063 
Liver  
Multiple** 56.0 (10.9) 631 0.3839 3.5 (3.5) 371 1 
Chi Square Analysis with population distribution above or below the mean of the total population (60.1 for Age of Diagnosis, 
2.12 for Disease Duration). Mean (s.d) is in years, represents Age of Diagnosis or Disease Duration 
* Control population compared to any antecedent condition population 
† N represents size of population with antecedent condition of interest and control population (no antecedent conditions) 
** Fisher’s exact test used due to small sample size for Age of Diagnosis and Disease Duration 
‡ Fisher’s exact test used due to small sample size for Disease Duration 
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Table 3. Categories of Antecedent Condition on Age of Diagnosis and Disease 
Duration, Chi Square Analysis 
 
Age of Diagnosis Disease Duration 
Antecedent Condition Mean (s.d) N P-value mean (s.d.) N P-value 
Cardiovascular  
1 62.8 (11.0) 762 <.0001 1.8 (1.8) 584 0.0002 
2 64.8 (11.0) 641 <.0001 1.7 (1.4) 486 0.0011 
3 63.3 (9.1) 508 <.0001 1.7 (1.7) 393 0.0196 
4* 63.5 (10.7) 461 0.1242 1.7 (1.2) 371 0.2462 
any 63.5 (10.8) 1357 <.0001 1.8 (1.7) 742 <.0001 
Autoimmune  
Sole Type 59.2 (12.5) 686 0.3806 2.7 (2.4) 396 0.1702 
Multiple Types 63.9 (10.7) 812 <.0001 2.1 (2.0) 466 0.6600 
Amount of Conditions  
1 61.3 (11.3) 747 <.0001 2.1 (2.0) 582 0.01 
2 65.0 (10.7) 663 <.0001 1.6 (1.4) 502 0.0002 
3 65.7 (10.0) 530 <.0001 1.4 (1.4) 412 0.0005 
4 62.7 (9.4) 478 0.0149 2.4 (1.9) 380 0.6715 
5* 64.8 (5.5) 456 0.0614 2.5 (2.4) 367 1 
6‡ 65.0† 454 0.3935 - - - 
Chi Square Analysis with population distribution above or below the mean of the total 
population (60.1 for Age of Diagnosis, 2.12 for Disease Duration). Mean (s.d.) is in years, 
represents Age of Diagnosis or Disease Duration 
† Sample size of one 
* Fisher’s exact test used due to small sample size for Age of Diagnosis and Disease Duration 
‡ Fisher’s exact test used due to small sample size for Age of Diagnosis 
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Table 4. Ordinal Logistic Regression Modeling of Age 
of Diagnosis and Disease Duration 
Model Variable Odds Ratio 
95% 
Confidence 
Interval 
Age of Diagnosis 
Blood Pressure 0.461 0.334 0.636 
Cholesterol 0.385 0.285 0.521 
Diabetes 0.711 0.458 1.104 
Obesity 2.268 1.494 3.443 
Asthma 1.001 0.588 1.705 
Arthritis 0.608 0.358 1.034 
COPD 0.419 0.212 0.826 
Neurological 0.303 0.072 1.279 
Kidney 0.375 0.106 1.322 
Liver 3.522 0.706 17.571 
Thyroid 0.896 0.615 1.306 
Race (Black) 1.577 1.2456 1.99767 
Race (Other) 0.676 0.563 0.81 
Gender (Female) 0.776 0.69235 0.87046 
Disease Duration 
Blood Pressure 1.06 0.705 1.595 
Cholesterol 1.048 0.723 1.518 
Diabetes 1.044 0.586 1.862 
Obesity 1.085 0.629 1.871 
Asthma 0.629 0.329 1.201 
Arthritis 0.919 0.48 1.759 
COPD 1.366 0.568 3.283 
Neurological 0.973 0.252 3.757 
Kidney 2.3 0.59 8.968 
Liver 0.347 0.081 1.485 
Thyroid 0.846 0.536 1.334 
Race (Black) 0.624 0.464 0.837 
Race (Other) 1.807 1.438 2.271 
Gender (Female) 1.080 0.938 1.241 
Age 1.049 1.036 1.062 
Race reference group is Caucasian. Gender reference group is Male. 
For age of diagnosis model, estimates above 1 lower the age of 
diagnosis. For disease duration, estimates above 1 shorten the 
duration. 
